Citadel Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-17,337
| Closed | -$916K | – | 11848 |
|
|
2020
Q3 | $916K | Sell |
17,337
-17,839
| -51% | -$1.1M | ﹤0.01% | 6198 |
|
|
2020
Q2 | $2.15M | Buy |
35,176
+5,117
| +17% | +$296K | ﹤0.01% | 4438 |
|
|
2020
Q1 | $1.7M | Sell |
30,059
-11
| -0% | -$627 | ﹤0.01% | 4406 |
|
|
2019
Q4 | $1.71M | Buy |
30,070
+8,313
| +38% | +$441K | ﹤0.01% | 4677 |
|
|
2019
Q3 | $1.16M | Buy |
21,757
+298
| +1% | +$17.3K | ﹤0.01% | 5328 |
|
|
2019
Q2 | $1.28M | Buy |
21,459
+9,701
| +83% | +$610K | ﹤0.01% | 5300 |
|
|
2019
Q1 | $733K | Buy |
+11,758
| New | +$778K | ﹤0.01% | 6135 |
|
|
2018
Q4 | – | Sell |
-5,819
| Closed | -$340K | – | 10078 |
|
|
2018
Q3 | $340K | Sell |
5,819
-68
| -1% | -$3.47K | ﹤0.01% | 7370 |
|
|
2018
Q2 | $264K | Buy |
+5,887
| New | +$253K | ﹤0.01% | 7428 |
|
|
2015
Q3 | – | Sell |
-9,384
| Closed | -$484K | – | 9396 |
|
|
2015
Q2 | $484K | Sell |
9,384
-3,936
| -30% | -$168K | ﹤0.01% | 5035 |
|
|
2015
Q1 | $522K | Sell |
13,320
-423
| -3% | -$16.6K | ﹤0.01% | 4847 |
|
|
2014
Q4 | $530K | Sell |
13,743
-868
| -6% | -$33.1K | ﹤0.01% | 4654 |
|
|
2014
Q3 | $516K | Buy |
14,611
+200
| +1% | +$5.87K | ﹤0.01% | 4573 |
|
|
2014
Q2 | $388K | Sell |
14,411
-2,337
| -14% | -$60.9K | ﹤0.01% | 4721 |
|
|
2014
Q1 | $434K | Buy |
+16,748
| New | +$402K | ﹤0.01% | 4555 |
|
Other funds holding BSTC
Citadel Advisors's BSTC Position: Q4 2020 in Review
Citadel Advisors sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 17,337 shares — an estimated $916K sold.
Citadel Advisors first reported a position in BSTC in Q1 2014 and held it in 15 quarters. The position peaked at $2.15M in Q2 2020. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Citadel Advisors reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 17,337 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $916K.
- Citadel Advisors first reported a position in BioSpecifics Technologies Corp. in Q1 2014 and held it in 15 quarters.
- Citadel Advisors's BioSpecifics Technologies Corp. position peaked at $2.15M in Q2 2020.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.